

## PRESS RELEASE

OCTOBER 11, 2021

### **Cerba HealthCare provides update on loan financing for acquisition of Lifebrain in Italy**

As previously announced, Cerba HealthCare, a leader in the field of medical diagnosis, has reached an agreement with European Laboratory Solutions (ELS) to acquire a 100% stake in the company for an EV of approximately EUR 1.2 billion, which owns the Lifebrain network in Italy. Once the acquisition completes, Cerba HealthCare will become the largest medical laboratory testing provider in Italy.

The syndication process for a proposed EUR 300 million incremental term loan, documented under Cerba's existing facilities and which will form part of the EUR 800 million debt financing for the acquisition, has commenced today.

Lifebrain had *pro forma* adjusted EBITDA (after COVID-19 normative adjustment and including certain synergies from Lifebrain's ongoing acquisitions and normalization adjustments) of EUR 86 million for the twelve months due June 30, 2021 and upon the making of the acquisition, the combined *pro forma* adjusted EBITDA for the enlarged group for the twelve months ended June 30, 2021 would have been EUR 502 million (after COVID-19 normative adjustment and including expected synergies from the acquisition).

*Pro forma* leverage following the transaction is marginally reduced with respect to the combined business (compared to the *pro forma* leverage of Cerba when it was acquired on June 30, 2021) and the acquisition is expected to close by the end of October.

For further information on the Lifebrain acquisition, please refer to our financial results webpage at <https://www.invest.cerbahealthcare.com/en/financial-results>.